large deviations from schedule [Regulatives / Guidelines]

posted by Helmut Homepage – Vienna, Austria, 2020-11-23 12:18 (147 d 05:20 ago) – Posting: # 22080
Views: 568

Hi yoyo87,

» […] accepted deviation in time in ambulatory samples (24, 36, 48 and 72 hr) in bioequivalence studies?? example 6 hours deviation is accepted or not??

[image]See also this recent thread. Well, six hours are extreme. I would even collect and analyze a 78 hr sample. Say, it was after the test-treatment and the reference was fine. If you don’t, you end up in your AUC0–tlast comparison with AUC0–48/AUC0–72, which is an apples-and-oranges comparison (negatively biased). If you do, you end up with AUC0–78/AUC0–72, which is positively biased.

Two options (have to be stated in the protocol):
  1. Specify a maximum acceptable deviation and – if exceeded – compare AUCs up to the last common time point* (here 48 hrs).
  2. If this an IR formulation, specify pAUC0–72 instead of AUC0–tlast as the PK metric for extent of absorption. Work with an imputed (estimated) concentration:
    \(C_0=\exp\left(\frac{\log_{e}C_1\cdot(t_2-t_0)+\log_{e}C_2\cdot(t_0-t_1)\;}{t_2-t_1} \right)\), where the indices \(\small{1,\,2}\) denote the times and concentrations before and after the estimate denoted by the index \(\small{0}\).
    Say, you have \(\small{t_1=48,\:C_1=16}\) and \(\small{t_2=78,\:C_2=5.0897}\).
    At \(\small{t_0=72}\) you will estimate \(\small{C_0\approx\exp\left(\frac{2.77259\times6+1.62722\times24}{30}\right)\approx6.400}\):


    See also the second example in this post.
NB, I recommend to always use the linear-up/logarithmic-down trapezoidal rule for the calculation of AUC.

Dif-tor heh smusma 🖖
Helmut Schütz

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

 Admin contact
21,419 posts in 4,475 threads, 1,510 registered users;
online 10 (0 registered, 10 guests [including 2 identified bots]).
Forum time: Monday 18:39 CEST (Europe/Vienna)

There is one certainty in drug development
and statistics that one can depend on:
the data are always late.    Scott Patterson and Byron Jones

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz